ToolGen Obtains Patent for 'Artificially Engineered Immune Cells'

[Asia Economy Reporter Minwoo Lee] ToolGen announced on the 10th that it has obtained a patent for 'Artificially Manipulated Immune Cells.'

The company explained, "This patent is a functional enhancement cancer immunotherapy cell platform technology," and added, "It will be developed as a cell therapy for various hematologic malignancies and solid tumors."